Skip to main content
search

News

Filter

Alentis announces positive topline results from two studies of Lixudebart

Anaveon appoints Dr. Richard Sachse as Chief Medical Officer

Stromal publishes groundbreaking research in Cell

Looking for an experienced biopharma professional for CEO role

Cimeio Therapeutics announces partnership with Kyowa Kirin to develop Novel Cell Therapies

metaLead joins BaseLaunch portfolio

Alentis Therapeutics raises $181.4 million in an oversubscribed series D financing

Synendos secures Innosuisse funding to advance clinical development of SYT-510

Key strategies for biotech companies transitioning from early- to late-stage

Alentis Therapeutics receives FDA IND clearance for ALE.P02, a novel CLDN1-ADC for the treatment of squamous cancers

MT-act joins BaseLaunch portfolio

We welcome Hoffmann & Partner as our new domain partner

BaseLaunch summer get-together 2024

NXI Therapeutics extends pre-seed funding to CHF 3.5 million ahead of major seed round

9 tips for scientists who want to become entrepreneurs

Nature publication demonstrating Cimeio`s transformative approach towards blood cancers

AbbVie becomes a BaseLaunch partner

Alentis appoints Alberto Toso Chief Scientific Officer

Our partnership with CSL

Our partnership with CSL

We welcome VISCHER as our new domain partner

Podcast: How to build a compelling pitch deck for early stage ventures

KPMG renews partnership with BaseLaunch

FimmCyte obtains CHF 1 million from the UZH Life Sciences Fund

Synendos Therapeutics granted EMA clinical trial authorisation

William Pao joins Alentis Therapeutics as independent board member

Novo Nordisk becomes a BaseLaunch partner

Engimmune Therapeutics strikes ‘fast-forward’ micro-fluidics collaboration with Swiss innovator CSEM

Ferring and PharmaBiome enter a collaboration and exclusive licensing agreement

TOLREMO treats first patient in phase I trial with TT125-802, a novel therapeutic agent to overcome transcriptional cancer drug resistance

T3 Pharma acquired by Boehringer Ingelheim for up to 450M Swiss francs

FDA clears Versameb’s VMB-100 for stress urinary incontinence treatment

Alentis Therapeutics doses first patient in phase 1/2 clinical trial of ALE.C04

FimmCyte announces the appointment of Dr. Markus Kalousek as chairperson

Onena Medicines secures 3.7 M Swiss francs investment

Johnson Johnson Innovation logo

Johnson & Johnson Innovation renews its commitment

Cimeio collaborating with the University of Pennsylvania

Insights into Roche’s partnering and venture fund strategies

Salvina Therapeutics joins BaseLaunch portfolio

TOLREMO therapeutics secures USD 39 million

Alentis Therapeutics receives FDA Fast Track Designation for ALE.C04

What you need to know about building your biotech startup

BaseLaunch Summer Get-Together 2023

Versameb strengthens its Board of Directors

Cimeio Therapeutics and Prime Medicine announce research collaboration

How Swiss life sciences startups can compete globally

Bridge Biotherapeutics’ partnering strategy and growth by external innovation

Phialogics AG appoints Prof. Dr. Erich Schlick as Chairman of its Board of Directors

Phialogics closed a €600k pre-seed financing round with HTGF

Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer

BaseLaunch Portfolio has raised over half a billion dollars to date!

Alentis Therapeutics closes $105M funding round Led by Jeito Capital, Novo Holdings and RA Capital Management

FimmCyte joins BaseLaunch Portfolio

What startups need to know about term sheets, legal due diligence and employee incentives

Building biotech companies and raising venture capital financing

Raising $50M series A with Cimeio Therapeutics

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

Do you have a question? Get in touch

  info@baselaunch.ch

Contact us
Close Menu